Dirk Schadendorf
Research Subjects
Research Interests
Dirk Schadendorf has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
A. Hauschild
8 shared publications- Claus Garbe
Centre for Dermatooncology, Department of Dermatology Eberhard Karls University Tuebingen Germany
5 shared publications - Selma Ugurel
Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany
5 shared publications A. Sucker
4 shared publicationsA. Zimpfer
3 shared publicationsR. Gutzmer
3 shared publications
Latest Publications
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi395
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
Background: VISMO is a first-in-class Hedgehog pathway inhibitor approved for the treatment of adult pts with advanced BCC. Pts with multiple BCCs, including those with BCC nevus syndrome, require long-term treatment with VISMO; however, continuous treatment may not be optimal over extended periods due to risk of chronic low-grade toxicity. MIKIE (NCT01815840) was designed to assess the efficacy and safety of two long-term intermittent VISMO dosing regimens in pts with multiple BCCs.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi395
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
Background: VISMO is a first-in-class Hedgehog pathway inhibitor approved for the treatment of adult pts with advanced BCC. Pts with multiple BCCs, including those with BCC nevus syndrome, require long-term treatment with VISMO; however, continuous treatment may not be optimal over extended periods due to risk of chronic low-grade toxicity. MIKIE (NCT01815840) was designed to assess the efficacy and safety of two long-term intermittent VISMO dosing regimens in pts with multiple BCCs.
- 18 December 2014
- Published by Elsevier in Annals of Oncology
- Vol. 26 (3) , 573-582
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival
Kinase inhibitors targeting the BRAF V600 mutation have become standard in the treatment of metastatic melanoma. Albeit in wide clinical use, the patterns associated with therapy outcome are not fully elucidated. The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib. This multicenter retrospective study analyzed patient, tumor, and pretreatment characteristics collected in BRAF V600-mutated stage IV melanoma patients before single-agent therapy with the BRAF inhibitor vemurafenib. A total of 300 patients from 14 centers were included into this study with a median follow-up time of 13.0 months. Median progression-free survival (PFS) was 5.1 months; median overall survival (OS) was 7.6 months. Best response under vemurafenib was associated with serum lactate dehydrogenase (LDH; ≤ versus >upper normal limit; P = 0.0000001), Eastern Cooperative Oncology Group (ECOG) overall performance status (OPS) (0 versus ≥1; P = 0.00089), and BRAF mutation subtype (V600E versus V600K; P = 0.016). Multivariate analysis identified ECOG OPS ≥1 [hazard ratio (HR) = 1.88; P = 0.00005], immunotherapy pretreatment (HR = 0.53; P = 0.0067), elevated serum LDH (HR = 1.45; P = 0.012), age >55 years (HR = 0.72; P = 0.019), and chemotherapy pretreatment (HR = 1.39; P = 0.036) as independent predictors of PFS. For OS, elevated serum LDH (HR = 1.99; P = 0.00012), ECOG OPS ≥1 (HR = 1.90; P = 0.00063), age >55 years (HR = 0.65; P = 0.011), kinase inhibitor pretreatment (HR = 1.86; P = 0.014), immunotherapy pretreatment (HR = 0.57; P = 0.025), chemotherapy pretreatment (HR = 2.17; P = 0.039), and male gender (HR = 0.70; 95% confidence interval 0.50–0.98; P = 0.039) were found as predictors. Our data demonstrate that the type of pretreatment strongly influences the outcome of vemurafenib therapy, with a precedent immunotherapy showing a positive, and a prior chemotherapy and kinase inhibitors showing a negative impact on survival, respectively. Moreover, we show that the patient's OPS, serum LDH, age, and gender independently impact vemurafenib therapy outcome. These findings should be taken into account for the future design of therapy sequencing in BRAF V600 mutation-positive melanoma patients.
- 18 December 2014
- Published by Elsevier in Annals of Oncology
- Vol. 26 (3) , 573-582
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival
Kinase inhibitors targeting the BRAF V600 mutation have become standard in the treatment of metastatic melanoma. Albeit in wide clinical use, the patterns associated with therapy outcome are not fully elucidated. The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib. This multicenter retrospective study analyzed patient, tumor, and pretreatment characteristics collected in BRAF V600-mutated stage IV melanoma patients before single-agent therapy with the BRAF inhibitor vemurafenib. A total of 300 patients from 14 centers were included into this study with a median follow-up time of 13.0 months. Median progression-free survival (PFS) was 5.1 months; median overall survival (OS) was 7.6 months. Best response under vemurafenib was associated with serum lactate dehydrogenase (LDH; ≤ versus >upper normal limit; P = 0.0000001), Eastern Cooperative Oncology Group (ECOG) overall performance status (OPS) (0 versus ≥1; P = 0.00089), and BRAF mutation subtype (V600E versus V600K; P = 0.016). Multivariate analysis identified ECOG OPS ≥1 [hazard ratio (HR) = 1.88; P = 0.00005], immunotherapy pretreatment (HR = 0.53; P = 0.0067), elevated serum LDH (HR = 1.45; P = 0.012), age >55 years (HR = 0.72; P = 0.019), and chemotherapy pretreatment (HR = 1.39; P = 0.036) as independent predictors of PFS. For OS, elevated serum LDH (HR = 1.99; P = 0.00012), ECOG OPS ≥1 (HR = 1.90; P = 0.00063), age >55 years (HR = 0.65; P = 0.011), kinase inhibitor pretreatment (HR = 1.86; P = 0.014), immunotherapy pretreatment (HR = 0.57; P = 0.025), chemotherapy pretreatment (HR = 2.17; P = 0.039), and male gender (HR = 0.70; 95% confidence interval 0.50–0.98; P = 0.039) were found as predictors. Our data demonstrate that the type of pretreatment strongly influences the outcome of vemurafenib therapy, with a precedent immunotherapy showing a positive, and a prior chemotherapy and kinase inhibitors showing a negative impact on survival, respectively. Moreover, we show that the patient's OPS, serum LDH, age, and gender independently impact vemurafenib therapy outcome. These findings should be taken into account for the future design of therapy sequencing in BRAF V600 mutation-positive melanoma patients.
- 1 December 2014
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 141 (12) , S288
Efficacité et tolérance à long terme du vismodégib dans le carcinome baso-cellulaire avancé : analyse finale à 30 mois de l’étude pivotale ERIVANCE
- 1 December 2014
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 141 (12) , S288
Efficacité et tolérance à long terme du vismodégib dans le carcinome baso-cellulaire avancé : analyse finale à 30 mois de l’étude pivotale ERIVANCE
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v1
Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma
Aim: No approved therapies exist that specifically target NRAS-mutant melanoma (≈ 20% of cases). In this study of BRAF V600- or NRAS-mutant melanoma, binimetinib, a potent and selective MEK1/2 inhibitor, was the first targeted therapy to show preliminary clinical activity in NRAS-advanced melanoma (Ascierto et al. Lancet Oncol, 2013). Methods: This is a phase 2 open-label single arm study of binimetinib 45 mg orally twice daily (bid) in patients with advanced/unresectable or metastatic BRAF V600- or NRAS-mutant melanoma. Updated efficacy, safety, and biomarker analyses of a larger NRAS-mutant subgroup than previously reported are presented here. Primary endpoint was objective response rate (ORR); secondary endpoints were progression-free survival (PFS) and overall survival (OS). Genomic profiling covering a panel of 293 clinically relevant cancer genes was conducted on pretreatment biopsies. Results: Patients with NRAS-mutant melanoma (n = 117) received binimetinib 45 mg bid. Median duration of exposure was 15.9 wks. ORR was 14.5% (1 CR, 16 PRs); disease control rate (≥SD) was 56%. Median PFS was 3.6 mos (95% CI, 2.6–3.8); median OS was 12.2 mos (Lower 95% CI, 7.9). The most common treatment-related adverse events (AEs) were dermatitis acneiform (54%), increased blood creatine phosphokinase (CK, 51%), and peripheral edema (42%). The most common grade 3/4 AE was increased blood CK (25%). Reduced pERK and DUSP6 expression demonstrated MAPK pathway inhibition by binimetinib; however, there was no clear association between efficacy and reduced expression, maybe due to limited data. Genetic landscape of a subset of patients (n = 78) with corresponding efficacy will be presented. CCND1 or CCND3 amplifications were exclusively seen in 5 patients with shorter PFS (≤3.6 mos), suggesting the hypothesis that constitutive CDK4/6 pathway signaling may play a role in resistance. Conclusions: Binimetinib 45mg bid is active in NRAS-mutant melanoma with an acceptable safety profile. A pivotal phase 3 study (NEMO) evaluating binimetinib in NRAS-mutant melanoma is ongoing. Understanding of the genetic landscape will be further refined from data collected in the NEMO study. Disclosure: C. van Herpen: has been on a board of directors and/or advisory board for Merck and has received research funding for Novartis and Merck; A. Hauschild: has received trial grants for Amgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD, Novartis, Oncosec, Roche. He has also consulted for and received honoraria from these companies and MedImmune; R. Dummer: has received research funding and consulted for Novartis; C. Berking: has consulted for Novartis, Roche, GSK, MSD, BMS, Astrazenca; received honoraria from Novartis, Roche, GSK, MSD, BMS; J.T. Beck: has received research funding from Novartis; D. Schadendorf: has been on a board of directors and/or advisory board, consulted for, and received honoraria from Novartis, GSK, Roche, BMS, Merck, Amgen; received research funding from Merck; G. Gibney: has been on a board of directors and/or advisory committee for and consulted for Genentech/Roche; P. Queirolo: has been on a board of directors and/or advisory committee for Roche, GSK, BMS; has consulted for Roche; received honoraria from GSK; P.A. Ascierto: received research funding from Novartis, Roche-Genentech, Ventana; been on a BOD or advisory committee for Novartis, Roche-Genentech, GSK, BMS; consulted for Roche-Genentech, MSD, GSK, Ventana, received honoraria from BMS, Roche-Genentech, GSK; C. Blank: has received research funding from Novartis and has been on a board of directors and/or advisory committee for Novartis, Roche, BMS, GSK, MSD; H. Nauwelaerts, F. Niazi, V. Antona and A. Zubel: is an employee of Novartis Pharma AG; R.R. Pal: is an employee of Novartis Healthcare Pvt. Ltd.; A. Reddy: is an employee of Novartis Pharmaceuticals Corporation; M.C. Heinrich: has received research funding from Novartis, Pfizer, Ariad, AROG; consulted for Novartis, Pfizer, Ariad, MolecularMD; received honoraria from Novartis, Pfizer, Ariad; owned stock in MolecularMD; provided expert testimony for Novartis. All other authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v1
Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma
Aim: No approved therapies exist that specifically target NRAS-mutant melanoma (≈ 20% of cases). In this study of BRAF V600- or NRAS-mutant melanoma, binimetinib, a potent and selective MEK1/2 inhibitor, was the first targeted therapy to show preliminary clinical activity in NRAS-advanced melanoma (Ascierto et al. Lancet Oncol, 2013). Methods: This is a phase 2 open-label single arm study of binimetinib 45 mg orally twice daily (bid) in patients with advanced/unresectable or metastatic BRAF V600- or NRAS-mutant melanoma. Updated efficacy, safety, and biomarker analyses of a larger NRAS-mutant subgroup than previously reported are presented here. Primary endpoint was objective response rate (ORR); secondary endpoints were progression-free survival (PFS) and overall survival (OS). Genomic profiling covering a panel of 293 clinically relevant cancer genes was conducted on pretreatment biopsies. Results: Patients with NRAS-mutant melanoma (n = 117) received binimetinib 45 mg bid. Median duration of exposure was 15.9 wks. ORR was 14.5% (1 CR, 16 PRs); disease control rate (≥SD) was 56%. Median PFS was 3.6 mos (95% CI, 2.6–3.8); median OS was 12.2 mos (Lower 95% CI, 7.9). The most common treatment-related adverse events (AEs) were dermatitis acneiform (54%), increased blood creatine phosphokinase (CK, 51%), and peripheral edema (42%). The most common grade 3/4 AE was increased blood CK (25%). Reduced pERK and DUSP6 expression demonstrated MAPK pathway inhibition by binimetinib; however, there was no clear association between efficacy and reduced expression, maybe due to limited data. Genetic landscape of a subset of patients (n = 78) with corresponding efficacy will be presented. CCND1 or CCND3 amplifications were exclusively seen in 5 patients with shorter PFS (≤3.6 mos), suggesting the hypothesis that constitutive CDK4/6 pathway signaling may play a role in resistance. Conclusions: Binimetinib 45mg bid is active in NRAS-mutant melanoma with an acceptable safety profile. A pivotal phase 3 study (NEMO) evaluating binimetinib in NRAS-mutant melanoma is ongoing. Understanding of the genetic landscape will be further refined from data collected in the NEMO study. Disclosure: C. van Herpen: has been on a board of directors and/or advisory board for Merck and has received research funding for Novartis and Merck; A. Hauschild: has received trial grants for Amgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD, Novartis, Oncosec, Roche. He has also consulted for and received honoraria from these companies and MedImmune; R. Dummer: has received research funding and consulted for Novartis; C. Berking: has consulted for Novartis, Roche, GSK, MSD, BMS, Astrazenca; received honoraria from Novartis, Roche, GSK, MSD, BMS; J.T. Beck: has received research funding from Novartis; D. Schadendorf: has been on a board of directors and/or advisory board, consulted for, and received honoraria from Novartis, GSK, Roche, BMS, Merck, Amgen; received research funding from Merck; G. Gibney: has been on a board of directors and/or advisory committee for and consulted for Genentech/Roche; P. Queirolo: has been on a board of directors and/or advisory committee for Roche, GSK, BMS; has consulted for Roche; received honoraria from GSK; P.A. Ascierto: received research funding from Novartis, Roche-Genentech, Ventana; been on a BOD or advisory committee for Novartis, Roche-Genentech, GSK, BMS; consulted for Roche-Genentech, MSD, GSK, Ventana, received honoraria from BMS, Roche-Genentech, GSK; C. Blank: has received research funding from Novartis and has been on a board of directors and/or advisory committee for Novartis, Roche, BMS, GSK, MSD; H. Nauwelaerts, F. Niazi, V. Antona and A. Zubel: is an employee of Novartis Pharma AG; R.R. Pal: is an employee of Novartis Healthcare Pvt. Ltd.; A. Reddy: is an employee of Novartis Pharmaceuticals Corporation; M.C. Heinrich: has received research funding from Novartis, Pfizer, Ariad, AROG; consulted for Novartis, Pfizer, Ariad, MolecularMD; received honoraria from Novartis, Pfizer, Ariad; owned stock in MolecularMD; provided expert testimony for Novartis. All other authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v1
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
Aim: BRAFi (D) and MEKi (T) each demonstrated superior progression-free survival (PFS) vs. chemotherapy in pts with BRAF V600E/K mutation-positive metastatic melanoma (MM). However, the emergence of disease resistance and development of cutaneous squamous cell carcinoma (cuSCC) are associated with BRAF inhibition. Simultaneous inhibition of BRAF and MEK mitigated these effects as shown in the Phase I/II study of D + T combination therapy vs. D monotherapy (NCT01072175) and the Phase III study of D + T combination therapy vs. D monotherapy (NCT01584648), with an improvement in overall response rate (ORR), PFS and reduced frequency of cuSCC. This Phase III study (NCT01597908) was conducted to establish superiority of D + T combination over V with respect to overall survival (OS) in pts with BRAF V600E/K mutation-positive MM. Methods: Pts were randomised 1:1 to receive D (150 mg twice daily [BID]) and T (2 mg once daily) vs. V monotherapy (960 mg BID) as first-line therapy. Eligible pts were ≥ 18 years old and had an ECOG performance status ≤ 1, with histologically confirmed, unresectable stage IIIC or IV, BRAF V600E/K mutation-positive MM. The primary endpoint was OS; secondary endpoints were PFS, ORR, duration of response, and safety. Crossover was prohibited. A pre-specified interim OS analysis was performed when 77% (222/288) of the total number of expected deaths, required for the protocol-specified final analysis, were observed; the study could be stopped for efficacy if the one-sided P value was < 0.0107. Results: From June 2012 to Oct 2013, 704 pts were randomised (352 to each arm). IDMC recommended stopping study based on an interim analysis which demonstrated an OS benefit that crossed the pre-specified efficacy stopping boundary for D + T combination. Rates of adverse events were generally similar for both arms and consistent with data from previous trials. Full efficacy and safety results will be presented at the meeting. Conclusions: D + T demonstrated a significant improvement in OS compared with V in pts with BRAF V600E/K mutation-positive MM. Disclosure: C. Robert: has received fees for Advisory Board participation from Bristol-Meyers Squibb, Roche, Merck, GlaxoSmithKline, Novartis and Amgen; P. Rutkowski: receives personal fees Novartis, Pfizer, GSK, and Roche, in addition to travel grants and fees for participation in speakers bureau and Advisory Boards from GSK and Novartis; R. Dummer: received grants and personal fees from GSK, Roche, Novartis, MSD and BMS; L. Mortier: received personal fees from GSK; V. Chiarion-Sileni: receiving compensation for Advisory Board participation GlaxoSmithKline, Bristol-Meyers Squibb and Roche; A. Hauschild: Consult, Hon and Trial funding: mgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche; P. Sun, S. Rubin and J. Legos: is an employee of GlaxoSmithKline and owns stock in the company; W. Crist: is an employee of GlaxoSmithKline; S.M. Little: is an employee and owns stock in GSK; D. Schadendorf: received personal fees, other support, and non-financial support from GlaxoSmithKline, Roche, Novartis, Amgen, Bristol-Meyers Squibb and MSD/Merck, and grants from MSD/Merck. All other authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v1
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
Aim: BRAFi (D) and MEKi (T) each demonstrated superior progression-free survival (PFS) vs. chemotherapy in pts with BRAF V600E/K mutation-positive metastatic melanoma (MM). However, the emergence of disease resistance and development of cutaneous squamous cell carcinoma (cuSCC) are associated with BRAF inhibition. Simultaneous inhibition of BRAF and MEK mitigated these effects as shown in the Phase I/II study of D + T combination therapy vs. D monotherapy (NCT01072175) and the Phase III study of D + T combination therapy vs. D monotherapy (NCT01584648), with an improvement in overall response rate (ORR), PFS and reduced frequency of cuSCC. This Phase III study (NCT01597908) was conducted to establish superiority of D + T combination over V with respect to overall survival (OS) in pts with BRAF V600E/K mutation-positive MM. Methods: Pts were randomised 1:1 to receive D (150 mg twice daily [BID]) and T (2 mg once daily) vs. V monotherapy (960 mg BID) as first-line therapy. Eligible pts were ≥ 18 years old and had an ECOG performance status ≤ 1, with histologically confirmed, unresectable stage IIIC or IV, BRAF V600E/K mutation-positive MM. The primary endpoint was OS; secondary endpoints were PFS, ORR, duration of response, and safety. Crossover was prohibited. A pre-specified interim OS analysis was performed when 77% (222/288) of the total number of expected deaths, required for the protocol-specified final analysis, were observed; the study could be stopped for efficacy if the one-sided P value was < 0.0107. Results: From June 2012 to Oct 2013, 704 pts were randomised (352 to each arm). IDMC recommended stopping study based on an interim analysis which demonstrated an OS benefit that crossed the pre-specified efficacy stopping boundary for D + T combination. Rates of adverse events were generally similar for both arms and consistent with data from previous trials. Full efficacy and safety results will be presented at the meeting. Conclusions: D + T demonstrated a significant improvement in OS compared with V in pts with BRAF V600E/K mutation-positive MM. Disclosure: C. Robert: has received fees for Advisory Board participation from Bristol-Meyers Squibb, Roche, Merck, GlaxoSmithKline, Novartis and Amgen; P. Rutkowski: receives personal fees Novartis, Pfizer, GSK, and Roche, in addition to travel grants and fees for participation in speakers bureau and Advisory Boards from GSK and Novartis; R. Dummer: received grants and personal fees from GSK, Roche, Novartis, MSD and BMS; L. Mortier: received personal fees from GSK; V. Chiarion-Sileni: receiving compensation for Advisory Board participation GlaxoSmithKline, Bristol-Meyers Squibb and Roche; A. Hauschild: Consult, Hon and Trial funding: mgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche; P. Sun, S. Rubin and J. Legos: is an employee of GlaxoSmithKline and owns stock in the company; W. Crist: is an employee of GlaxoSmithKline; S.M. Little: is an employee and owns stock in GSK; D. Schadendorf: received personal fees, other support, and non-financial support from GlaxoSmithKline, Roche, Novartis, Amgen, Bristol-Meyers Squibb and MSD/Merck, and grants from MSD/Merck. All other authors have declared no conflicts of interest.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , TPS232
DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma.
TPS232 Background: Clinical activity of the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) was observed in a Phase II study in patients with metastatic melanoma (NCT00086866) and in a Phase II study in patients with completely resected non-small cell lung cancer (NSCLC) (NCT00290355). Based on these positive signals for the activity of MAGE-A3 ASCI, a Phase III trial is currently ongoing in patients with resectable regionally advanced melanoma (DERMA Phase III trial, NCT00796445). Methods: DERMA is a double-blind, placebo-controlled, 2:1 randomized trial of MAGE-A3 ASCI vs. Placebo. Eligible patients must have cutaneous melanoma expressing MAGE-A3 with histologically proven macroscopic nodal disease (AJCC Stage IIIB-C). Central randomization uses an internet-based algorithm accounting for the following factors: Stage of the disease (IIIB, IIIC and IIITx), TNM nodal category (N1, N2 and N3), primary category (Tx-0 or T1-2 or T3 or T4), extracapsular extension (Yes, No), study center, prior treatment with IFN or anti-CTLA-4 (Yes, No). Patients must have had complete surgical resection of all tumor. Disease-Free Survival (DFS) in the overall patient population is the primary endpoint, while overall survival, safety and health-related quality of life (EQ-5D) are secondary endpoints. A previously-defined gene signature associated with MAGE-A3 ASCI benefit is also being validated as a secondary endpoint of this trial (Louahed et al., EORTC-NCI-AACR 2009). The MAGE-A3 ASCI combines the tumor-specific antigen MAGE-A3, delivered as a recombinant protein, with the immunostimulant AS15. A maximum of 13 doses are administered by intramuscular injection over 27 months; the first 5 are given at 3-week intervals followed by 8 at 12-week intervals. This Phase III trial is designed to enroll 1300 patients from 250 centers worldwide. Since Dec 1, 2008, 2426 patients have been screened. From 1917 tumor samples valid for testing the expression of MAGE-A3, 1265 express MAGE-A3 (MAGE-A3 expression rate of 66%). 832 patients are currently enrolled to this study.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , TPS232
DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma.
TPS232 Background: Clinical activity of the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) was observed in a Phase II study in patients with metastatic melanoma (NCT00086866) and in a Phase II study in patients with completely resected non-small cell lung cancer (NSCLC) (NCT00290355). Based on these positive signals for the activity of MAGE-A3 ASCI, a Phase III trial is currently ongoing in patients with resectable regionally advanced melanoma (DERMA Phase III trial, NCT00796445). Methods: DERMA is a double-blind, placebo-controlled, 2:1 randomized trial of MAGE-A3 ASCI vs. Placebo. Eligible patients must have cutaneous melanoma expressing MAGE-A3 with histologically proven macroscopic nodal disease (AJCC Stage IIIB-C). Central randomization uses an internet-based algorithm accounting for the following factors: Stage of the disease (IIIB, IIIC and IIITx), TNM nodal category (N1, N2 and N3), primary category (Tx-0 or T1-2 or T3 or T4), extracapsular extension (Yes, No), study center, prior treatment with IFN or anti-CTLA-4 (Yes, No). Patients must have had complete surgical resection of all tumor. Disease-Free Survival (DFS) in the overall patient population is the primary endpoint, while overall survival, safety and health-related quality of life (EQ-5D) are secondary endpoints. A previously-defined gene signature associated with MAGE-A3 ASCI benefit is also being validated as a secondary endpoint of this trial (Louahed et al., EORTC-NCI-AACR 2009). The MAGE-A3 ASCI combines the tumor-specific antigen MAGE-A3, delivered as a recombinant protein, with the immunostimulant AS15. A maximum of 13 doses are administered by intramuscular injection over 27 months; the first 5 are given at 3-week intervals followed by 8 at 12-week intervals. This Phase III trial is designed to enroll 1300 patients from 250 centers worldwide. Since Dec 1, 2008, 2426 patients have been screened. From 1917 tumor samples valid for testing the expression of MAGE-A3, 1265 express MAGE-A3 (MAGE-A3 expression rate of 66%). 832 patients are currently enrolled to this study.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 8520
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.
8520 Background: Vemurafenib (V; RG7204, PLX4032), an oral inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety, efficacy, and pharmacokinetics in dose escalation and melanoma extension cohorts from the Phase I study (n=87; Flaherty, et al. NEJM, 2010). Development of cuSCC/KA was observed in melanoma patients (pts). Here we describe further molecular characterization of confirmed cases of cuSCC/KA. Methods: Pts receiving V therapy were monitored for toxicity including development of skin lesions. Suspicious lesions were excised and sent to central laboratories for confirmation of cuSCC/KA histology and for molecular analysis. Analyses included genetic analysis of H/K/N-RAS, CDKN2A and TP53, as well as P53 protein expression. Results: 35 cuSCC/KA lesions developed in 15 pts during therapy—34/35 (97%) were diagnosed as SCC, KA type or SCC, with features of KA and 1/35 (3%) were diagnosed as SCC, without features of KA. All lesions were histologically well differentiated and were managed with complete local excision. No lesions recurred and therapy was not interrupted. The majority of lesions developed within 8–21 wks after initiation of therapy. Genetic analyses were performed on 21 cuSCC/KA from 10 melanoma pts. 15/21 (71%) had mutations at codons 12, 13 or 61 of H-, K- or NRAS (with 14/15 having an HRAS mutation). No specimens had BRAF mutations in exon 15. A CDKN2A mutation was observed in 1/21 (5%) lesions (A73V) and 4/18 (22%) had exonic TP53 mutations. P53 nuclear expression varied, but was highest in the samples with P53 mutations (C176W and Y236C). Conclusions: CuSCC/KA lesions that developed during V therapy had a high incidence of RAS mutations in codons commonly mutated in sporadic cuSCC/KAs in the general population (HRAS mutation rate 12–46%, Nouri K., Skin Cancer, 2008). Given the short latency between exposure to V and the development of cuSCC/KA, these preliminary findings suggest that skin cells with pre-existing RAS mutations may develop into these lesions upon exposure to V. Further investigation and larger sample size is needed to determine if RAS alone or additional factors are required to induce cuSCC/KA.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 8520
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.
8520 Background: Vemurafenib (V; RG7204, PLX4032), an oral inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety, efficacy, and pharmacokinetics in dose escalation and melanoma extension cohorts from the Phase I study (n=87; Flaherty, et al. NEJM, 2010). Development of cuSCC/KA was observed in melanoma patients (pts). Here we describe further molecular characterization of confirmed cases of cuSCC/KA. Methods: Pts receiving V therapy were monitored for toxicity including development of skin lesions. Suspicious lesions were excised and sent to central laboratories for confirmation of cuSCC/KA histology and for molecular analysis. Analyses included genetic analysis of H/K/N-RAS, CDKN2A and TP53, as well as P53 protein expression. Results: 35 cuSCC/KA lesions developed in 15 pts during therapy—34/35 (97%) were diagnosed as SCC, KA type or SCC, with features of KA and 1/35 (3%) were diagnosed as SCC, without features of KA. All lesions were histologically well differentiated and were managed with complete local excision. No lesions recurred and therapy was not interrupted. The majority of lesions developed within 8–21 wks after initiation of therapy. Genetic analyses were performed on 21 cuSCC/KA from 10 melanoma pts. 15/21 (71%) had mutations at codons 12, 13 or 61 of H-, K- or NRAS (with 14/15 having an HRAS mutation). No specimens had BRAF mutations in exon 15. A CDKN2A mutation was observed in 1/21 (5%) lesions (A73V) and 4/18 (22%) had exonic TP53 mutations. P53 nuclear expression varied, but was highest in the samples with P53 mutations (C176W and Y236C). Conclusions: CuSCC/KA lesions that developed during V therapy had a high incidence of RAS mutations in codons commonly mutated in sporadic cuSCC/KAs in the general population (HRAS mutation rate 12–46%, Nouri K., Skin Cancer, 2008). Given the short latency between exposure to V and the development of cuSCC/KA, these preliminary findings suggest that skin cells with pre-existing RAS mutations may develop into these lesions upon exposure to V. Further investigation and larger sample size is needed to determine if RAS alone or additional factors are required to induce cuSCC/KA.